Form DEFA14A PORTOLA PHARMACEUTICALS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Portola Pharma (PTLA) Misses Q1 EPS by 9c
May 5, 2016 5:28 PM EDTPortola Pharma (NASDAQ: PTLA) reported Q1 EPS of ($1.15), $0.09 worse than the analyst estimate of ($1.06). Revenue for the quarter came in at $8.3 million versus the consensus estimate of $7.91 million.
For earnings history and earnings-related data on Portola Pharma (PTLA) click here.
... More